Get the Stockscreener App
96.75
0.03%
-0.03
Overview
News
Price History
Option Chain
Financials
Why RVTY Down?
Discussions
Forecast
Stock Split
Dividend History
Revvity Inc stock is traded at $96.75, with a volume of 557.14K.
It is down -0.03% in the last 24 hours and down -7.56% over the past month.
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.
See More
Previous Close:
$96.78
Open:
$96.97
24h Volume:
557.14K
Relative Volume:
0.40
Market Cap:
$10.97B
Revenue:
$2.77B
Net Income/Loss:
$286.61M
P/E Ratio:
41.17
EPS:
2.35
Net Cash Flow:
$524.11M
1W Performance:
+0.53%
1M Performance:
-7.56%
6M Performance:
-2.06%
1Y Performance:
-14.00%
1-Day Range:
$95.87
$97.09
1-Week Range:
$95.87
$98.55
52-Week Range:
$81.36
$128.28
Revvity Inc Stock (RVTY) Company Profile
Name
Revvity Inc
Sector
Industry
Phone
781-663-6900
Address
77 4TH AVENUE, WALTHAM
Compare RVTY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RVTY
Revvity Inc
|
96.75 | 10.97B | 2.77B | 286.61M | 524.11M | 2.35 |
|
TMO
Thermo Fisher Scientific Inc
|
580.74 | 217.58B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
230.32 | 163.50B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
688.48 | 54.95B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
138.39 | 39.21B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
IQV
Iqvia Holdings Inc
|
226.92 | 38.49B | 15.90B | 1.28B | 2.21B | 7.2842 |
Revvity Inc Stock (RVTY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-15-25 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-25 | Initiated | Goldman | Neutral |
| Oct-16-25 | Initiated | Guggenheim | Neutral |
| May-01-25 | Upgrade | UBS | Neutral → Buy |
| Jan-10-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-13-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-15-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Equal Weight |
| Jul-08-24 | Initiated | Leerink Partners | Outperform |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | UBS | Buy → Neutral |
| Jan-04-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Jul-19-23 | Initiated | Raymond James | Outperform |
| May-23-23 | Resumed | Goldman | Buy |
View All
Revvity Inc Stock (RVTY) Latest News
Can Revvity Inc. stock deliver strong annual returnsPortfolio Risk Assessment & Rapid Portfolio Trading - bollywoodhelpline.com
Revvity Earnings Notes - Trefis
Revvity advances AI-driven scientific discovery with Signals Xynthetica - MSN
Q3 Earnings Highlights: Revvity (NYSE:RVTY) Vs The Rest Of The Research Tools & Consumables Stocks - Yahoo Finance
Revvity Inc. stock outperforms competitors on strong trading day - MarketWatch
(RVTY) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Did Revvity’s New AI Discovery Platform (RVTY) Quietly Redefine Its Innovation Moat? - simplywall.st
Revvity introduces AI-augmented design platform for molecular and materials discovery - BioSpectrum India
Aug Patterns: How Revvity Inc stock reacts to global recession fearsJuly 2025 Summary & Safe Capital Growth Trade Ideas - moha.gov.vn
Is Revvity Inc. stock a defensive play in 2025Global Markets & Stepwise Trade Signal Implementation - Улправда
How cyclical is Revvity Inc. stock compared to rivalsJuly 2025 Price Swings & Comprehensive Market Scan Reports - DonanımHaber
Revvity Advances AI-Driven Scientific Discovery With Signals Xynthetica - TradingView — Track All Markets
Will Revvity Inc. stock reach all time highs in 2025Weekly Trade Report & Expert Verified Stock Movement Alerts - DonanımHaber
Raymond James reiterates Outperform rating on Revvity stock after site visit - Investing.com Nigeria
Raymond James reiterates Outperform rating on Revvity stock after site visit By Investing.com - Investing.com India
What consensus target says about Revvity Inc. stockRate Cut & AI Optimized Trade Strategies - DonanımHaber
Why Revvity Inc. stock could outperform in 2025Weekly Profit Analysis & Precise Buy Zone Tips - DonanımHaber
Will Revvity Inc. stock benefit from automationJuly 2025 Closing Moves & Technical Buy Zone Confirmations - Улправда
Is Revvity Inc. stock a buy on dipsWeekly Trading Summary & Daily Price Action Insights - Улправда
What analyst consensus says on Revvity Inc. stockInsider Selling & Proven Capital Preservation Tips - Улправда
Revvity (BSP:R1VT34) EV-to-OCF : 22.14 (As of Dec. 18, 2025) - GuruFocus
Will Revvity Inc. stock see PE expansionMarket Activity Summary & High Conviction Buy Zone Picks - ulpravda.ru
Revvity to Present at J.P. Morgan Healthcare Conference - Business Wire
Does Revvity (NYSE:RVTY) Have A Healthy Balance Sheet? - simplywall.st
How is Revvity's stock performance compared to other health care stocks? - MSN
Revvity (NYSE: RVTY) officer disposes 25 shares for RSU tax withholding - Stock Titan
3 Reasons RVTY is Risky and 1 Stock to Buy Instead - The Globe and Mail
Revvity unveils AI-powered Signals Xynthetica to accelerate molecular and materials design - Indian Pharma Post
Revvity Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Revvity to launch AI models-as-a-service for scientific discovery - Investing.com Nigeria
Revvity Introduces Signals Xynthetica, an AI-Augmented Design Platform for Molecular and Materials D - PharmiWeb.com
Revvity Introduces New AI Service for Molecular, Materials Design - marketscreener.com
Revvity, Inc. Introduces Signals Xynthetica, an AI-Augmented Design Platform for Molecular and Materials Discovery - marketscreener.com
Barclays Maintains Revvity (RVTY) Overweight Recommendation - Nasdaq
Revvity Introduces Signals Xynthetica, an AI-Augmented Design Platform for Molecular and Materials Discovery - Yahoo Finance
Revvity Inc. stock underperforms Monday when compared to competitors - MarketWatch
Revvity Shares Fall After BofA Downgrade - marketscreener.com
Revvity stock rating downgraded to Neutral by BofA Securities - Investing.com South Africa
Revvity (NYSE:RVTY) Lowered to "Neutral" Rating by Bank of America - MarketBeat
Barclays Adjusts Price Target on Revvity to $115 From $105, Maintains Overweight Rating - marketscreener.com
Wells Fargo Adjusts Price Target on Revvity to $107 From $102, Maintains Equalweight Rating - marketscreener.com
BofA Securities Downgrades Revvity to Neutral From Buy - marketscreener.com
How Is Revvity's Stock Performance Compared to Other Health Care Stocks? - Barchart.com
EdgePoint Investment Group Inc. Boosts Stock Position in Revvity Inc. $RVTY - MarketBeat
Revvity Inc. stock underperforms Friday when compared to competitors - MarketWatch
Federated Hermes Inc. Cuts Position in Revvity Inc. $RVTY - MarketBeat
The Goldman Sachs Group Begins Coverage on Revvity (NYSE:RVTY) - MarketBeat
Goldman Sachs initiates coverage of Revvity (RVTY) with neutral recommendation - MSN
Revvity Inc Stock (RVTY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
0.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):